Trial Profile

A taste assessment trial of ACER-001

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium phenylbutyrate (Primary)
Indications Inborn urea cycle disorders; Maple syrup urine disease
Focus Adverse reactions
Sponsors Acer Therapeutics

Most Recent Events

21 Nov 2019 New trial record
13 Nov 2019 According to an Acer Therapeutics media release, the company anticipates enrolling the first subjects in 1H 2020. The design and size of the trial will be determined following further discussions with the FDA.
13 Nov 2019 According to an Acer Therapeutics media release, the company initiated a taste assessment trial of three different formulations of ACER-001 (multi-particulate powder) assessed relative to BUPHENYL (powder) using certified taste-testers. Results expected in Q4 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com